This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Plioplys, A. V. Search for Related Content PubMed PubMed Citation Articles by Plioplys, A. V. Social Bookmarking                         What's this?

Intravenous Immunoglobulin Treatment of Children With Autism

Mercy Hospital and Medical Center, and the Department of Neurology, University of Illinois, Chicago, IL

Since autism has been associated with immunologic abnormalities suggesting an autoimmune cause of autistic symptoms in a subset of patients, this study was undertaken to investigate whether intravenous immunoglobulin (IVIg) would improve autistic symptoms. Ten autistic children with immunologic abnormalities, demonstrated on blood tests, were enrolled in this study. Their ages ranged from 4 to 17 years, with two girls and eight boys. Eight children (1 female and 7 male) historically had undergone autistic regression. Intravenous immunoglobulin, 200 to 400 mg/kg, was administered every 6 weeks for an intended treatment program of four infusions. In five children, there was no detectable change in behavior during the treatment program. In four children, there was a mild improvement noted in attention span and hyperactivity. In none of these children did the parents feel that the improvement was sufficient to warrant further continuation of the infusions beyond the termination of the program. Only in one child was there a very significant improvement, with almost total amelioration of autistic symptoms over the time period of the four infusions. Once the treatment program was completed, this child gradually deteriorated over a 5-month time period and fully reverted to his previous autistic state. In this treatment program, five children had no response to intravenous immunoglobulin. In the four children who showed mild improvements, those improvements may simply have been due to nonspecific effects of physician intervention and parental expectation (ie, placebo effect). However, in one child there was a very significant amelioration of autistic symptoms. There were no distinguishing historic or laboratory features in this child who improved. Given a positive response rate of only 10% in this study, along with the high economic costs of the immunologic evaluations and the intravenous immunoglobulin treatments, the use of intravenous immunoglobulin to treat autistic children should be undertaken only with great caution, and only under formal research protocols. (J Child Neurol 1998;13:79-82).

Journal of Child Neurology, Vol. 13, No. 2, 79-82 (1998)
DOI: 10.1177/088307389801300207


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. M. Myers, C. P. Johnson, and the Council on Children With Disabilities Management of Children With Autism Spectrum Disorders Pediatrics, November 1, 2007; 120(5): 1162 - 1182. [Abstract] [Full Text] [PDF]

				Committee on Children With Disabilities Technical Report: The Pediatrician's Role in the Diagnosis and Management of Autistic Spectrum Disorder in Children Pediatrics, May 1, 2001; 107(5): 85e - 85. [Abstract] [Full Text]

				A. M. Comi, A. W. Zimmerman, V. H. Frye, P. A. Law, and J. N. Peeden Familial Clustering of Autoimmune Disorders and Evaluation of Medical Risk Factors in Autism J Child Neurol, June 1, 1999; 14(6): 388 - 394. [Abstract] [PDF]